Vaccines in oncology: background and clinical potential.
Cancer is one of the leading causes of death in Western society. Despite improvements in screening, diagnosis and treatment of cancer, many patients ultimately succumb to their disease. Advances in molecular biology and our increased understanding of how the immune system functions have led to an intense interest in the development of cancer vaccines.
Armstrong
A C
AC
CRC Department of Medical Oncology, University of Manchester & Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, UK.
Hawkins
R E
RE
D000951:Antigens, Neoplasm / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology; D001327:Autoimmune Diseases / Q000276:immunology; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D000939:Epitopes; D016147:Genes, Tumor Suppressor; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D009154:Mutation; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000951:Antigens, Neoplasm; D000956:Antigens, Viral; D019496:Cancer Vaccines; D002272:Carcinoembryonic Antigen; D000939:Epitopes; D015395:Histocompatibility Antigens Class I; D007130:Immunoglobulin Idiotypes